Pulmonary vascular obstruction following administration of high-energy nucleotides.
D000227:Adenine Nucleotides / Q000494:pharmacology; D000531:Altitude; D000818:Animals; D001792:Blood Platelets / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D002245:Carbon Dioxide / Q000097:blood; D002417:Cattle; D003597:Cytosine Nucleotides / Q000494:pharmacology; D006150:Guanine Nucleotides / Q000494:pharmacology; D006339:Heart Rate; D006863:Hydrogen-Ion Concentration; D006976:Hypertension, Pulmonary / Q000139:chemically induced*; D009705:Nucleosides / Q000494:pharmacology; D009711:Nucleotides / Q000494:pharmacology*; D010092:Oximetry; D011651:Pulmonary Artery / Q000187:drug effects*; D011652:Pulmonary Circulation / Q000187:drug effects*; D011687:Purines / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D014500:Uracil Nucleotides / Q000494:pharmacology; D014666:Vasomotor System / Q000187:drug effects*
D000227:Adenine Nucleotides; D003597:Cytosine Nucleotides; D006150:Guanine Nucleotides; D009705:Nucleosides; D009711:Nucleotides; D011687:Purines; D014500:Uracil Nucleotides; D002245:Carbon Dioxide